000 01391nam a22004097a 4500
001 D0001C000194
003 DOH
005 20210505150229.0
008 210505b ||||| |||| 00| 0 eng d
245 0 0 _aSafety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults :
_binterim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study /
_c Paul A Goepfert [and twenty two others]
580 _aLancet Infect Dis . 2021 Apr 19; S1473-3099 (21) 00147-X. doi: 10.1016/S1473-3099(21)00147-X
650 2 _aCOVID-19 Vaccines
_ximmunology
650 2 _aPlacebo Effect
700 1 _a Goepfert, Paul A
700 1 _aFu, Bo
700 1 _aChabanon, Anne-Laure
700 1 _aBonaparte, Matthew I
700 1 _aDavis, Matthew G
700 1 _aEssink, Brandon J
700 1 _aFrank, Ian
700 1 _aHaney, Owen
700 1 _aJanosczyk, Helene
700 1 _aKeefer, Michael C
700 1 _aKoutsoukos, Marguerite
700 1 _aKimmel, Murray A
700 1 _aMasotti, Roger
700 1 _aSavarino, Stephen J
700 1 _aSchuerman, Lode
700 1 _aSchwartz, Howard
700 1 _aSher, Lawrence D
700 1 _aSmith, Jon
700 1 _aTavares-Da-Silva, Fernanda
700 1 _aGurunathan, Sanjay
700 1 _aGranados, Carlos A Diaz
700 1 _ade Bruyn, Guy
942 _cJA
999 _c4417
_d4417